title: Can radioimmunotherapy promote from an orphan drug to daily clinical practice?
authors.affiliation: Department of Nuclear Medicine, University Hospital RWTH Aachen University, Pauwelsstr. 30, 52057, Aachen, Germany, fmottaghy@ukaachen.de.
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000532:radiotherapy*; D006801:Humans; D007162:Immunoproteins / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D019063:Tenascin / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007162:Immunoproteins; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C000594969:Tenarad; D019063:Tenascin